Form 4: Gyre Therapeutics President Sells Shares Under 10b5-1 Trading Plan
SEC Form 4 Filing
Songjiang Ma, President of Gyre Therapeutics, sold shares of common stock on January 27 and 28, 2025, under a pre-arranged 10b5-1 trading plan.
Summary
- Songjiang Ma, President of Gyre Therapeutics, sold 2,000 shares of common stock on January 27, 2025, at a weighted average price of $11.18.
- He also sold 2,000 shares on January 28, 2025, at a weighted average price of $11.51.
- These transactions were executed under a Rule 10b5-1 trading plan adopted on September 13, 2024.
- Following these transactions, Ma directly owns no shares, but his spouse indirectly owns 2,895,138 shares.
Sentiment
Score: 5
Explanation: The document is a standard SEC Form 4 filing, indicating insider trading activity. The sentiment is neutral as it simply reports transactions.
Industry Context
Sales by company presidents are common and are often pre-planned to avoid accusations of insider trading. The use of a 10b5-1 plan allows insiders to sell shares at predetermined times and prices.
Stakeholder Impact
- The sale of shares by a company president could be perceived negatively by some shareholders, but the existence of a 10b5-1 plan mitigates this concern.
Key Dates
| Date | Description |
|---|---|
| 09/13/2024 | Date of adoption of the Rule 10b5-1 trading plan |
| 01/27/2025 | Date of first transaction: Sale of 2,000 shares |
| 01/28/2025 | Date of second transaction: Sale of 2,000 shares |
| 01/29/2025 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.